Related Experiment Video
Updated: Jun 9, 2026

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma
Watcharin Loilome1, Sirinun Juntana, Nisana Namwat
1Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Abstract:
The protein kinase A regulatory subunit 1 alpha (PRKAR1A/PKAI) pathway is overexpressed in varieties of tumors and cancer cell lines including cholangiocarcinoma (CCA), although its role in CCA growth modulation is unclear. In our study, we evaluated the effect of PRKAR1A/PKAI targeting on CCA cell proliferation. Real-time PCR demonstrated an increased mRNA expression of PRKAR1A/PKAI, whereas protein kinase A regulatory subunit 2 beta (PRKAR2B/PKAII) was downregulated in human CCA tissues and CCA cell lines. Immunohistochemistry of human CCA tissues revealed increased PRKAR1A with decreased PRKAR2B protein expression. Moreover, CCA cell lines showed abundantly expressed PRKAR1A, while lacking PRKAR2B expression. Silencing PRKAR1A expression induced growth inhibition and apoptosis of CCA cells, with an associated decrease in mitogen-activated protein kinases, PI3K/Akt, JAK/STAT and Wnt/β-catenin pathway signaling. The inhibition of PKA using a PKA inhibitor and cAMP analogs also led to a significant cell growth inhibition. In conclusion, our study reports the overexpression as well as molecular mechanisms by which PRKAR1A/PKA regulates human CCA cell growth. Importantly, abrogation of gene expression caused significant CCA cell growth inhibition, oncogenic signaling and coupled apoptosis induction, suggesting PRKAR1A's potential as a drug target for CCA therapy.
Insights
Targeting the PRKAR1A/PKAI pathway inhibits cholangiocarcinoma (CCA) cell growth. Silencing PRKAR1A/PKAI induced apoptosis and reduced oncogenic signaling, suggesting PRKAR1A/PKAI as a potential CCA therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The PRKAR1A/PKAI pathway is implicated in various cancers.
- Its specific role in cholangiocarcinoma (CCA) growth remains largely undefined.
Purpose of the Study:
- To investigate the effect of targeting PRKAR1A/PKAI on CCA cell proliferation.
- To elucidate the molecular mechanisms underlying PRKAR1A/PKAI's role in CCA.
Main Methods:
- Real-time PCR and immunohistochemistry to assess PRKAR1A and PRKAR2B expression in CCA tissues and cell lines.
- Gene silencing of PRKAR1A and inhibition of PKA signaling.
- Analysis of downstream signaling pathways including MAPK, PI3K/Akt, JAK/STAT, and Wnt/β-catenin.
Main Results:
- PRKAR1A/PKAI was upregulated, while PRKAR2B/PKAII was downregulated in CCA.
- PRKAR1A silencing significantly inhibited CCA cell proliferation and induced apoptosis.
- Targeting PRKAR1A/PKAI reduced activity in key oncogenic signaling pathways.
Conclusions:
- PRKAR1A/PKA overexpression drives human CCA cell growth through specific molecular pathways.
- Abrogating PRKAR1A/PKA expression effectively inhibits CCA cell growth, induces apoptosis, and suppresses oncogenic signaling.
- PRKAR1A presents a promising therapeutic target for CCA treatment.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Abnormal Proliferation
